K2 Principal Fund, L.P. I Teos Therapeutics, Inc. Transaction History

K2 Principal Fund, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$5.97 - $8.15 $174,192 - $237,800	29,178 New	29,178 $174,000
Q3 2024 Nov 15, 2024	BUY	$10.09 - $17.97 $2.8 Million - $4.99 Million	277,871 Added 108.09%	534,951 $5.46 Million
Q2 2024 Aug 14, 2024	BUY	$10.33 - $18.09 $2.45 Million - $4.29 Million	237,080 Added 1185.4%	257,080 $3.82 Million
Q1 2024 May 14, 2024	BUY	$9.89 - $13.64 $197,800 - $272,800	20,000 New	20,000 $272,000

4.22M

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $361M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.